|

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

RECRUITINGN/ASponsored by Montefiore Medical Center
Actively Recruiting
PhaseN/A
SponsorMontefiore Medical Center
Started2026-08-17
Est. completion2028-02
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations8 sites

Summary

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms. The study compares two ways of connecting people to treatment: Referral to a community treatment provider (usual care before the new program begins). Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider. Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes. The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective. The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. ≥ 18 years old;
2. Meet DSM-5 criteria for moderate or severe OUD;
3. Interest in receiving buprenorphine treatment;
4. Speaks English or Spanish;
5. Currently an SSP client at the time of enrollment;
6. Ability to provide informed consent.

Exclusion Criteria:

1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;
2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;
3. Allergy to buprenorphine;
4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.

Conditions4

CancerOpioid Use DisorderOpioid Use Disorder, ModerateOpioid Use Disorder, Severe

Locations8 sites

Community Health Project Los Angeles (CHPLA)
Site PI323-380-5469info@chpla.org
HIPS
Washington D.C., District of Columbia, 20002
Phyllis Bijole202-834-3289phyllis@hips.org
CARPBR/Be Safe Syringe Program
Baton Rouge, Louisiana, 70806
Site PI225-775-7988gjvar.carpbr@gmail.com
Harm Reduction Sisters
Duluth, Minnesota, 55805
Jack Research Coordinator218-206-6482jack@harmreductionsisters.org
Alianza of New Mexico
Roswell, New Mexico, 88203
Ryan Nix Site PI575-623-1995ryan.nix@alianzanm.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.